COMPASS Pathways (CMPS) Projected to Post Earnings on Thursday

COMPASS Pathways (NASDAQ:CMPS) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect COMPASS Pathways to post earnings of ($0.62) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

COMPASS Pathways Stock Performance

CMPS stock opened at $4.54 on Friday. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a market cap of $310.63 million, a P/E ratio of -2.06 and a beta of 2.28. COMPASS Pathways has a 12-month low of $3.16 and a 12-month high of $12.75. The stock’s 50 day simple moving average is $4.09 and its 200 day simple moving average is $5.39.

Wall Street Analyst Weigh In

CMPS has been the subject of several research analyst reports. Maxim Group reduced their price objective on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Finally, HC Wainwright dropped their price target on shares of COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $30.60.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.